 Home > Active Ingredient News > Immunology News > Mult Scler: The seroconversion rate of patients with relapsing-remitting multiple sclerosis is reduced after the application of a single SARS-COV-2 vaccine

Mult Scler: The seroconversion rate of patients with relapsing-remitting multiple sclerosis is reduced after the application of a single SARS-COV-2 vaccine

 Last Update: 2021-10-19
 Source: Internet
 Author: User

Tags

1 figure

prolene 4 0

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Background: Patients taking immunosuppressive drugs are given priority for SARS-COV-2 vaccine
.

Several SARS-COV-2 vaccines have been proven effective in individuals with immunity, emphasizing the results of humoral immunity

Patients taking immunosuppressive drugs are given priority for SARS-COV-2 vaccine

Method: We use highly sensitive Luminex to detect SARS-COV-2 immunoglobulin G (IgG) after ocrelizumab receptor vaccination
.

Results: SARS-COV-2-IgG was detected in 44.
1% of patients 21+ days after a vaccination, regardless of vaccine type (AZD1222 vs BNT162b2, odds ratio (OR) = 0.
62, 95% confidence interval (CI) = 0.
157 -2.
32, p = 0.
72)
.

The B cell count can significantly predict seroconversion (β1 = 12.

Figure (A) The patients who were known to be negative before vaccination (N=34) can detect SARS-COV-2IgG (through the target epitope) after one dose of the vaccine
.

(B)-(E) Univariate analysis of CD19 counts, IgM, IgG, and the interval between the first vaccination and the injection of Orizizumab (subgroups with matching blood types before and after the first vaccination, N=34)

Figure (A) The patients who were known to be negative before vaccination (N=34) can detect SARS-COV-2IgG (through the target epitope) after one dose of the vaccine

The humoral response of patients with CD20 exhaustion after receiving a dose of the new coronary pneumonia vaccine was lower than expected

Georgieva ZG, Dӧffinger R, Kumararatne D,et al, Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients .

Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

High Purity 99% BPN14770 Zatolmilast 1606974-33-7 In Stock Fast Ship to USA

CAS No.: 1606974-33-7

Pharm Grade

$1-1.1/UNIT FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Top quantity Imiquimod CAS NO 99011-02-6 White crystalline powder 99% API

CAS No.: 99011-02-6

Pharmacy Grade

$1800-1850/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.